Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS)
Although half of the respondents reported experiencing side effects, 39.0% of past users identified side effects as a reason for discontinuation. This suggests a gap between patient experience and perceived reasons for discontinuation. A notable finding from the study is the significant role of healthcare providers in influencing the decisions to start or stop sMRA treatment. Therefore, future research should focus on exploring the factors that shape healthcare providers' decision-making processes when initiating and discontinuing treatment options.
Authors
- Alain Gay (ORCID: https://orcid.org/0000-0002-0689-7168)
- Vincent J. Willey (ORCID: https://orcid.org/0000-0002-6473-6469)
- Judith J. Stephenson (ORCID: https://orcid.org/0000-0003-2747-935X)
- Elena Pessina
- Charlie Scott (ORCID: https://orcid.org/0000-0002-2816-4889)
- Nihar R. Desai (ORCID: https://orcid.org/0000-0003-2384-2545)
- Nikolaus G. Oberprieler
- Kerstin Folkerts
- Rakesh K. Singh (ORCID: https://orcid.org/0000-0003-3235-9934)
- Emma Richard
- Chia‐Chen Teng
Institutions
- Clarion University (US)
- Bayer (Norway) (NO)
- Eli Lilly (United States) (US)
- Yale University (US)
- EP Analytics (United States) (US)
- Bayer (Italy) (IT)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Pragmatic and Observational Research
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/por.s489802
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00